AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Withdrawn) A method for preventing cancer comprising administering to a human or animal an effective amount of the growth factor vaccine composition of Claim 3.
- 2. (Withdrawn) The method of Claim 1, wherein the growth factor consists of SEQ ID NO: 10.
- 3. (Previously Presented) An immunogenic composition comprising an immunogenic peptide fragment, wherein the immunogenic peptide fragment comprises SEQ ID NO: 10.
 - 4. (Cancelled).
- 5. (Previously Presented) The composition of Claim 3, further comprising a pharmaceutically acceptable carrier.
- 6. (Previously Presented) The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, vesiciles, colloidal gold, or carrier proteins.
- 7. (Previously Presented) The composition of Claim 6, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells or polymers of D and/or L-amino acids.
- 8. (Previously Presented) The composition of Claim 3, further comprising adjuvants, preservatives, diluents, emulsifiers, or stabilizers.

Amendment and Response to Office Action Serial No. 10/799,163 Page 4 of 6

9. (Previously Presented) The composition of Claim 8, wherein the adjuvant

is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block

polymers, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β-

(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants,

saponin derivative adjuvants, killed Bordetella pertussis, lipopolysaccharide of gram-negative

bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and

aluminum phosphate.

10. (Previously Presented) A composition for reducing hyperproliferative

disorders comprising administering to a human or animal an effective amount of a growth factor

vaccine composition wherein the composition comprises SEQ ID NO: 10.

11. (Previously Presented) The composition of Claim 10, wherein the

hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia,

metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis,

Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases,

rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasias, arthritis, diabetic

neovascularizations, macular degeneration, wound healing, peptic ulcer, Helicobacter related

diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation,

placentation, or cat scratch fever.

12. (Previously Presented) A composition for reducing cancer comprising

administering to a human or animal an effective amount of a growth factor vaccine composition

wherein the composition comprises SEQ ID NO: 10.

13. (Previously Presented) A composition for inhibiting tumor growth and

metastasis comprising administering to a human or animal an effective amount of a growth factor

vaccine composition wherein the composition comprises SEQ ID NO: 10.